drugset
drugset / Trial / NCT03775928

Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer

NCT03775928 ↗

Phase 2 Unknown 80 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus capecitabine or capecitabine for maintenance therapy of patients with with advanced triple-negative breast cancer

Timeline

Start
2018-12-18
Primary completion
2020-12-01
Completion
2021-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivoceranib Small molecule 425 mg Oral
Background Capecitabine Small molecule 1000 mg/m2 —

Indications

triple-negative breast carcinoma